- Report
- January 2024
- 200 Pages
Global
From €3624EUR$4,150USD£3,148GBP
- Report
- May 2024
- 135 Pages
Global
From €5676EUR$6,499USD£4,931GBP
- Report
- May 2024
- 130 Pages
Global
From €5676EUR$6,499USD£4,931GBP
- Report
- March 2020
- 183 Pages
Global
From €3886EUR$4,450USD£3,376GBP
- Report
- February 2024
- 111 Pages
Global
From €4148EUR$4,750USD£3,604GBP
- Report
- August 2022
- 111 Pages
Global
From €4148EUR$4,750USD£3,604GBP
- Report
- February 2024
- 110 Pages
Global
From €4148EUR$4,750USD£3,604GBP
- Report
- April 2023
- 115 Pages
Global
From €4148EUR$4,750USD£3,604GBP
- Report
- July 2024
- 150 Pages
Global
From €2183EUR$2,500USD£1,897GBP
- Drug Pipelines
- July 2020
- 50 Pages
Global
From €1747EUR$2,000USD£1,517GBP
- Report
- August 2024
- 240 Pages
Global
From €4322EUR$4,949USD£3,755GBP
- Report
- May 2023
- 81 Pages
Global
From €3500EUR$4,293USD£3,147GBP
- Report
- May 2023
- 93 Pages
Global
From €3500EUR$4,293USD£3,147GBP
The Neurological Drug market is composed of drugs used to treat diseases and disorders of the Central Nervous System (CNS). These drugs are used to treat a wide range of conditions, including Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and stroke. CNS drugs are also used to treat psychiatric disorders, such as depression, anxiety, and schizophrenia. These drugs are typically administered orally, intravenously, or intramuscularly.
The Neurological Drug market is highly competitive, with many large pharmaceutical companies competing for market share. Companies such as Pfizer, Merck, Novartis, and GlaxoSmithKline are some of the major players in the market. Other companies, such as Eli Lilly, AstraZeneca, and Sanofi, also have a presence in the market. Additionally, there are many smaller companies that specialize in the development and manufacture of CNS drugs. Show Less Read more
